baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 12/24 GS71/ DE000HD03463 /

5/16/2024 9:46:03 PM	Chg.-0.0800	Bid9:59:15 PM	Ask9:59:15 PM	Underlying	Strike price	Expiration date	Option type
0.9200EUR	-8.00%	0.8700 Bid Size: 4,000	0.9300 Ask Size: 4,000	GSK PLC LS-,3125	19.00 -	12/18/2024	Call

GlobeNewswire 5/16 Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

GlobeNewswire 5/15 Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire 5/13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

GlobeNewswire 5/10 iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 5/10 iTeos Therapeutics Announces $120 Million Registered Direct Offering

GlobeNewswire 5/9 Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/9 Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...

GlobeNewswire 5/9 Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...

GlobeNewswire 5/9 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/9 Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

GlobeNewswire 5/9 Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

GlobeNewswire 5/8 SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 5/8 Alector Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/8 Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...

GlobeNewswire 5/8 Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in ...

GlobeNewswire 5/7 BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Roun...

GlobeNewswire 5/1 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TeleTrader 5/1 British FTSE 100 opens higher amid data, eyes on Fed

TeleTrader 5/1 GSK: Q1 revenue increases 6% to £7.3 billion

GlobeNewswire 4/30 SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the Euro...

GlobeNewswire 4/30 Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial o...

GlobeNewswire 4/29 Immutep Quarterly Activities Report Q3 FY24

GlobeNewswire 4/25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 4/23 Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and R...

GlobeNewswire 4/22 Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its ...

UC WAR. CALL 12/24 GS71/ DE000HD03463 /

If you wish to receive reply to your feedback, please provide your email address.